ethyl 6-(1-benzyloxycarbonyl-4-piperidyl)-2-mesyloxyhexanoate | 100277-32-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 6-(1-benzyloxycarbonyl-4-piperidyl)-2-mesyloxyhexanoate
• 英文别名: ethyl 6-(1-benzyloxycarbonyl-4-piperidyl)-2-methanesulfonyloxyhexanoate；benzyl 4-(6-ethoxy-5-methylsulfonyloxy-6-oxohexyl)piperidine-1-carboxylate
• CAS: 100277-32-5
• 化学式: C₂₂H₃₃NO₇S
• 分子量: 455.573
• InChiKey: WDDYDEQRFZDLNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  31
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  108
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  ethyl 6-(1-benzyloxycarbonyl-4-piperidyl)-2-mesyloxyhexanoate 生成 N--L-alanyl>-N-(2-indanyl)glycine
  参考文献：
  名称：

  SUGIHARA, HIROSADA;NISHIKAWA, KOHEI;ITO, KATSUMI

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl 6-(1-benzyloxycarbonyl-4-piperidyl)-2-oxohexanoate 在 sodium cyanoborohydride 作用下， 以 吡啶 、 乙醇 、 水 、 溶剂黄146 为溶剂， 反应 5.5h， 生成 ethyl 6-(1-benzyloxycarbonyl-4-piperidyl)-2-mesyloxyhexanoate
  参考文献：
  名称：

  Synthesis and angiotensin converting enzyme-inhibitory activity of 1,5-benzothiazepine and 1,5-benzoxazepine derivatives. III.

  摘要：

  一系列具有(S)-1-羧基-ω-(4-哌啶基)烷基基团的(R)-3-氨基-4-氧代-2, 3, 4, 5-四氢-1, 5-苯噻氮卓-5-乙酸（8）和(S)-3-氨基-4-氧代-2, 3, 4, 5-四氢-1, 5-苯并噻氮卓-5-乙酸（9）被制备，作为寻找具有长效作用的血管紧张素转化酶（ACE）抑制剂的一部分。在哌啶基烷基部分中，碳链的长度(n)从二到六进行了变化，以确定最佳结构。在静脉注射和口服给药中，观察到(R)-3-[(S)-1-羧基-5-(4-哌啶基)戊基]氨基-4-氧代-2, 3, 4, 5-四氢-1, 5-苯噻氮卓-5-乙酸（8c：CV-5975）具有最持久的体内活性。

  DOI：

  10.1248/cpb.34.3747

文献信息

• An improved synthesis of the new angiotensin converting enzyme inhibitor CV-5975 via a chemoenzymatic process.
  作者：MASAKUNI KORI、KATSUMI ITOH、HIROSADA SUGIHARA

  DOI：10.1248/cpb.35.2319

  日期：——

  A chemoenzymatic synthesis of the new angiotensin converting enzyme inhibitor CV-5975 (1) is described. The optically active key intermediate for the synthesis of 1, ethyl (R) -6- (1-benzyloxycarbonyl-4-piperidyl) -2-hydroxyhexanoate ((R) -4), was prepared by kinetic resolution of the racemic α-hydroxyester ((RS) -4) with a lipase and also by asymmetric reduction of the α-oxoester (3) with baker's yeast. The enantiomeric excess (ee) of the α-hydroxyester ((R) -4) produced by these enzymatic procedures exceeded 60%. This optically active alcohol ((R) -4) was converted to its mesylate ((R) -5), which was then subjected to SN2 reaction with the aminobenzothiazepine derivative (2) followed by deprotection to yield 1.

  本文描述了一种新型血管紧张素转换酶抑制剂 CV-5975 (1) 的化学合成方法。合成 1 的光学活性关键中间体(R) -6-(1-苄氧羰基-4-哌啶基) -2-羟基己酸乙酯（(R) -4）是通过外消旋α-羟酯（(RS) -4）与脂肪酶的动力学解析以及α-氧酯（3）与面包酵母的不对称还原制备的。通过这些酶解方法制得的α-羟酯（(R) -4）的对映体过量（ee）超过了 60%。这种具有光学活性的醇（(R) -4）被转化为其甲磺酸酯（(R) -5），然后与氨基苯并硫氮杂卓衍生物（2）发生 SN2 反应，再进行脱保护，得到 1。
• Condensed seven-membered ring compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04638000A1

  公开（公告）日：1987-01-20

  Novel condensed seven-membered ring compounds of the formula: ##STR1## [wherein R.sup.1 and R.sup.2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy, or both jointly form tri- or tetramethylene; R.sup.3 and R.sup.5 are independently hydrogen, lower alkyl or aralkyl; R.sup.4 is hydrogen or lower alkyl; R.sup.6 is a condensed or non-condensed hetero-alicyclic containing at least one atom of N, O and S as a ring-forming atom which may be substituted; A is an alkylene chain; n is 1 or 2] and salts thereof. These compounds exhibit inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of circulatory diseases, such as hypertension, cardiopathy and cerebral apoploxy.

  该文献介绍了一类新型的七元环化合物，化学式为：##STR1## [其中R.sup.1和R.sup.2独立地是氢、卤素、三氟甲基、低碳基或低氧基，或共同形成三或四亚甲基；R.sup.3和R.sup.5独立地是氢、低碳基或芳基碳基；R.sup.4是氢或低碳基；R.sup.6是含有至少一个N、O和S原子作为环形成原子的紧缩或非紧缩杂环，该杂环可能被取代；A是一种烷基链；n为1或2]及其盐。这些化合物表现出抑制肾素-血管紧张素转化酶等活性，并且在循环疾病的诊断、预防和治疗中具有价值，如高血压、心脏病和脑中风。
• Piperidine derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04954625A1

  公开（公告）日：1990-09-04

  Novel compounds of the formula: ##STR1## [wherein A is an .alpha.-amino acid residue; B is a group represented by the formula: ##STR2## wherein R.sup.4 is hydrogen, lower alkyl, aralkyl or amino-lower alkyl), whereby the linkage between the symbols A and B designates a peptide bond and the group R.sup.4 in B may be linked with A; R.sup.1 is hydrogen, lower alkyl or aralkyl; R.sup.2 is hydrogen, lower alkyl, aralkyl or acyl; X is alkylene] and salts thereof posses, for example, inhibitory activity on angiotensin converting enzyme, and are useful as an agent for diagnosis, prevention or treatment of hypertension as well as circulatory diseases such as cardiopathy and cerebral apoplexy.

  该公式的新化合物：##STR1## [其中A是α-氨基酸残基；B是由公式表示的基团：##STR2## 其中R.sup.4是氢、低碳基、芳基烷基或氨基-低碳基），其中符号A和B之间的连接表示肽键，基团B中的R.sup.4可以与A连接；R.sup.1是氢、低碳基或芳基烷基；R.sup.2是氢、低碳基、芳基烷基或酰基；X是烷基]及其盐具有例如对血管紧张素转换酶的抑制活性，并且可用作诊断、预防或治疗高血压以及心血管疾病如心脏病和脑卒中的药物。
• Intermediates for the preparation of condensed seven-membered ring
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04739066A1

  公开（公告）日：1988-04-19

  Novel condensed seven-membered ring compounds of the formula: ##STR1## [wherein R.sup.1 and R.sup.2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy, or both jointly form tri- or tetramethylene; R.sup.3 and R.sup.5 are independently hydrogen, lower alkyl or aralkyl; R.sup.4 is hydrogen or lower alkyl; R.sup.6 is a condensed or non-condensed hetero-alicyclic containing at least one atom of N, O and S as a ring-forming atom which may be substituted; A is an alkylene chain; n is 1 or 2] and salts thereof. These compounds exhibit inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of circulatory diseases, such as hypertension, cardiopathy and cerebral apoploxy.

  这是一种化合物的化学式：##STR1## [其中R.sup.1和R.sup.2分别为氢、卤素、三氟甲基、低碳基或低碳氧基，或共同形成三亚甲基或四亚甲基；R.sup.3和R.sup.5分别为氢、低碳基或芳基低碳基；R.sup.4为氢或低碳基；R.sup.6为含有至少一个N、O和S原子作为环形成原子的紧缩或非紧缩杂环，可以被取代；A是一个烷基链；n为1或2]和它们的盐。这些化合物表现出对血管紧张素转换酶等的抑制活性，并且作为诊断、预防和治疗循环系统疾病（如高血压、心脏病和脑中风）的药物具有价值。
• Piperidine derivatives
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04816466A1

  公开（公告）日：1989-03-28

  Novel Compounds of the formula: ##STR1## [wherein A is an .alpha.-amino acid residue; B is a group represented by the formula: ##STR2## (wherein R.sup.4 is hydrogen, lower alkyl, aralkyl or amino-lower alkyl), whereby the linkage between the symbols A and B designates a peptide bond and the group R.sup.4 is B may be linked with A; R.sup.1 is hydrogen, lower alkyl or aralkyl; R.sup.2 is hydrogen, lower alkyl, aralkyl or acyl; X is alkylene] and salts thereof posses, for example, inhibitory activity on angiotension converting enzyme, and are useful as an agent for diagnosis, prevention or treatment of hypertension as well as circulatory diseases such as cardiopathy and cerebral apoplexy.

  式子为：##STR1##的新化合物[其中A为α-氨基酸残基；B为由式子##STR2##表示的基团（其中R.sup.4为氢、低烷基、芳基烷基或氨基-低烷基），A和B之间的连接表示肽键，且基团R.sup.4可以与A连接；R.sup.1为氢、低烷基或芳基烷基；R.sup.2为氢、低烷基、芳基烷基或酰基；X为烷基）及其盐具有抑制血管紧张素转化酶的活性，可用作高血压、心脏病和脑卒中的诊断、预防或治疗剂。